1
|
Zanin J, Rance G. Objective Determination of Site-of-Lesion in Auditory Neuropathy. Ear Hear 2024:00003446-990000000-00348. [PMID: 39294863 DOI: 10.1097/aud.0000000000001589] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/21/2024]
Abstract
OBJECTIVE Auditory neuropathy (AN), a complex hearing disorder, presents challenges in diagnosis and management due to limitations of current diagnostic assessment. This study aims to determine whether diffusion-weighted magnetic resonance imaging (MRI) can be used to identify the site and severity of lesions in individuals with AN. METHODS This case-control study included 10 individuals with AN of different etiologies, 7 individuals with neurofibromatosis type 1 (NF1), 5 individuals with cochlear hearing loss, and 37 control participants. Participants were recruited through the University of Melbourne's Neuroaudiology Clinic and the Murdoch Children's Research Institute specialist outpatient clinics. Diffusion-weighted MRI data were collected for all participants and the auditory pathways were evaluated using the fixel-based analysis metric of apparent fiber density. Data on each participant's auditory function were also collected including hearing thresholds, otoacoustic emissions, auditory evoked potentials, and speech-in-noise perceptual ability. RESULTS Analysis of diffusion-weighted MRI showed abnormal white matter fiber density in distinct locations within the auditory system depending on etiology. Compared with controls, individuals with AN due to perinatal oxygen deprivation showed no white matter abnormalities ( p > 0.05), those with a neurodegenerative conditions known/predicted to cause VIII cranial nerve axonopathy showed significantly lower white matter fiber density in the vestibulocochlear nerve ( p < 0.001), while participants with NF1 showed lower white matter fiber density in the auditory brainstem tracts ( p = 0.003). In addition, auditory behavioral measures of speech perception in noise and gap detection were correlated with fiber density results of the VIII nerve. CONCLUSIONS Diffusion-weighted MRI reveals different patterns of anatomical abnormality within the auditory system depending on etiology. This technique has the potential to guide management recommendations for individuals with peripheral and central auditory pathway abnormality.
Collapse
Affiliation(s)
- Julien Zanin
- Department of Audiology and Speech Pathology, The University of Melbourne, Parkville, Melbourne, Australia
- The HEARing Cooperative Research Centre, Melbourne, Victoria, Australia
| | - Gary Rance
- Department of Audiology and Speech Pathology, The University of Melbourne, Parkville, Melbourne, Australia
- The HEARing Cooperative Research Centre, Melbourne, Victoria, Australia
| |
Collapse
|
2
|
Zhao S, Che F, Yang L, Zheng Y, Wang D, Yang Y, Wang Y. First report of paternal uniparental disomy of chromosome 8 with SLC52A2 mutation in Brown-vialetto-van laere syndrome type 2 and an analysis of genotype-phenotype correlations. Front Genet 2022; 13:977914. [PMID: 36186484 PMCID: PMC9520306 DOI: 10.3389/fgene.2022.977914] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2022] [Accepted: 08/23/2022] [Indexed: 11/17/2022] Open
Abstract
Purpose: This study reports the clinical and genetic features of Brown-Vialetto-Van Laere syndrome (BVVL) type 2 in a case of uniparental disomy of chromosome 8 in mainland China and analyzes the genotype-phenotype correlation through a review of the literature of BVVL type 2 cases. Methods: The clinical characteristics, treatment, and follow-up data of the patient were summarized, and the etiology was identified by whole-exome sequencing and gene chip analysis. Correlations between the genotype and phenotype were analyzed by collecting clinical and genetic data of published cases and our patient. Results: We identified a homozygous mutation in SLC52A2 (NM_001253815.2 c.1255G>A) by trio-WES. Sanger sequencing confirmed that his father was heterozygous and his mother was wild type. Subsequently, paternal uniparental disomy of chromosome 8 [UPD (8)pat] was confirmed by chromosomal microarray analysis.The patient received long-term oral riboflavin treatment (7 mg/kg.d) and was followed up for 40 months by which time the child’s bulbar palsy, ataxia, and motor function had improved. A review of the literature and statistical analysis found that the symptoms of BVVL type 2 appear at the earliest shortly after birth and at the latest at 10 years of age. The median age of onset was 2.5 years, but the overall delay in diagnosis was a median of 5.6 years. The most common symptoms were hearing loss (83.9%), followed by muscle weakness (80.6%), visual impairment (64.5%), and ataxia (61.3%). To date, a total of 32 mutations in the SLC52A2 gene have been reported, with the most common being a missense mutation. Mutations occur throughout the length of the gene apart from at the N-terminus. In patients with missense mutations, homozygous pattern was more likely to present with ataxia as the first symptom (p < 0.05), while compound heterozygous pattern was more likely to develop respiratory insufficiency during the course of disease (p < 0.001). Moreover, patients with one missense mutation located in inside the transmembrane domain were more likely to have respiratory insufficiency than those with mutations both inside and outside the domain (p < 0.05). Riboflavin supplementation was an important factor in determining prognosis (p < 0.001). Conclusion: We report the first UPD(8)pat with SLC52A2 homozygous pathogenic mutation case in BVVL type 2, which expand the mutation spectrum of gene.
Collapse
Affiliation(s)
- Siyu Zhao
- Department of Pediatric neurology, Xi’an Children’s hospital, Xi’an, China
| | - Fengyu Che
- Shaanxi Institute of Pediatric Diseases, Xi’an Children’s Hospital, Xi’an, China
| | - Le Yang
- Department of Pediatric neurology, Xi’an Children’s hospital, Xi’an, China
| | - Yanyan Zheng
- Department of Pediatric neurology, Xi’an Children’s hospital, Xi’an, China
| | - Dong Wang
- Department of Pediatric neurology, Xi’an Children’s hospital, Xi’an, China
| | - Ying Yang
- Shaanxi Institute of Pediatric Diseases, Xi’an Children’s Hospital, Xi’an, China
- *Correspondence: Ying Yang, Yan Wang,
| | - Yan Wang
- Department of Pediatric neurology, Xi’an Children’s hospital, Xi’an, China
- *Correspondence: Ying Yang, Yan Wang,
| |
Collapse
|
3
|
The audiovestibular profile of Brown-Vialetto-Van Laere syndrome. The Journal of Laryngology & Otology 2021; 135:1000-1009. [PMID: 34496984 DOI: 10.1017/s0022215121002395] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND Brown-Vialetto-Van Laere syndrome, a rare disorder associated with motor, sensory and cranial nerve neuropathy, is caused by mutations in riboflavin transporter genes SLC52A2 and SLC52A3. Hearing loss is a characteristic feature of Brown-Vialetto-Van Laere syndrome and has been shown in recent studies to be characterised by auditory neuropathy spectrum disorder. METHOD This study reports the detailed audiovestibular profiles of four cases of Brown-Vialetto-Van Laere syndrome with SLC52A2 and SLC52A3 mutations. All of these patients had auditory neuropathy spectrum disorder. RESULTS There was significant heterogeneity in vestibular function and in the benefit gained from cochlear implantation. The audiological response to riboflavin therapy was also variable, in contrast to generalised improvement in motor function. CONCLUSION We suggest that comprehensive testing of vestibular function should be conducted in Brown-Vialetto-Van Laere syndrome, in addition to serial behavioural audiometry as part of the systematic examination of the effects of riboflavin.
Collapse
|
4
|
Gedik Soyuyuce O, Ayanoglu Aksoy E, Yapici Z. A case report of sudden-onset auditory neuropathy spectrum disorder associated with Brown-Vialetto-Van Laere syndrome (riboflavin transporter deficiency). Int J Audiol 2021; 61:258-264. [PMID: 33983862 DOI: 10.1080/14992027.2021.1921291] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
OBJECTIVE The purpose of this paper is to describe a child with auditory neuropathy spectrum disorder (ANSD) associated with Brown-Vialetto-Van Laere (BVVL) syndrome, which is a rare, inherited, neurodegenerative disorder that is caused by defects in riboflavin transporter genes. DESIGN We report the audiological and clinical profile of a child who presented with a complaint of sudden loss of speech understanding associated with an atypical form of ANSD. He was later diagnosed with BVVL. STUDY SAMPLE An 11-year-old boy with ANSD associated with BVVL. RESULTS The patient's severe neurological symptoms improved within a year of supplementation with high doses of riboflavin. His fluctuating hearing loss and 0% WDS remained unchanged. The patient was able to use hearing aids without any discomfort after treatment initiation, but he stopped using them again due to a lack of benefit in speech understanding. Although cochlear implantation was recommended, the patient and his family decided not to consider it for another year since they still had hope for complete recovery. CONCLUSIONS Sudden-onset ANSD can be the earliest sign of undetected BVVL syndrome. Early detection of BVVL is crucial since all symptoms can be reversible with an early intervention of high doses of riboflavin supplementation.
Collapse
Affiliation(s)
| | | | - Zuhal Yapici
- Department of Neurology, Division of Child Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
| |
Collapse
|
5
|
Niceforo A, Marioli C, Colasuonno F, Petrini S, Massey K, Tartaglia M, Bertini E, Moreno S, Compagnucci C. Altered cytoskeletal arrangement in induced pluripotent stem cells (iPSCs) and motor neurons from patients with riboflavin transporter deficiency. Dis Model Mech 2021; 14:dmm.046391. [PMID: 33468503 PMCID: PMC7927654 DOI: 10.1242/dmm.046391] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2020] [Accepted: 01/05/2021] [Indexed: 12/28/2022] Open
Abstract
The cytoskeletal network plays a crucial role in differentiation, morphogenesis, function and homeostasis of the nervous tissue, so that alterations in any of its components may lead to neurodegenerative diseases. Riboflavin transporter deficiency (RTD), a childhood-onset disorder characterized by degeneration of motor neurons (MNs), is caused by biallelic mutations in genes encoding the human riboflavin (RF) transporters. In a patient- specific induced Pluripotent Stem Cells (iPSCs) model of RTD, we recently demonstrated altered cell-cell contacts, energy dysmetabolism and redox imbalance.The present study focusses on cytoskeletal composition and dynamics associated to RTD, utilizing patients' iPSCs and derived MNs. Abnormal expression and distribution of α- and β-tubulin (α- and β-TUB), as well as imbalanced tyrosination of α-TUB, accompanied by impaired ability to repolymerize after nocodazole treatment, were found in RTD patient-derived iPSCs. Following differentiation, MNs showed consistent changes in TUB content, which was associated with abnormal morphofunctional features, such as neurite length and Ca++ homeostasis, suggesting impaired differentiation.Beneficial effects of RF supplementation, alone or in combination with the antioxidant molecule N-acetyl-cystine (NAC), were assessed. RF administration resulted in partially improved cytoskeletal features in patients' iPSCs and MNs, suggesting that redundancy of transporters may rescue cell functionality in the presence of adequate concentrations of the vitamin. Moreover, supplementation with NAC was demonstrated to be effective in restoring all the considered parameters, when used in combination with RF, thus supporting the therapeutic use of both compounds.
Collapse
Affiliation(s)
- Alessia Niceforo
- Department of Science, Laboratorio Interdipartimentale di Microscopia Elettronica, University Roma Tre, Rome 00146, Italy
- Department of Neuroscience, Unit of Neuromuscular and Neurodegenerative Diseases, Laboratory of Molecular Medicine, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Pediatrico Bambino Gesù, Rome 00146, Italy
| | - Chiara Marioli
- Genetics and Rare Diseases Research Division, IRCCS Ospedale Pediatrico Bambino Gesù, Rome 00146, Italy
| | - Fiorella Colasuonno
- Department of Science, Laboratorio Interdipartimentale di Microscopia Elettronica, University Roma Tre, Rome 00146, Italy
- Department of Neuroscience, Unit of Neuromuscular and Neurodegenerative Diseases, Laboratory of Molecular Medicine, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Pediatrico Bambino Gesù, Rome 00146, Italy
| | - Stefania Petrini
- Confocal Microscopy Core Facility, Research Laboratories, IRCCS Ospedale Pediatrico Bambino Gesù, Rome 00146, Italy
| | - Keith Massey
- Science Director, Cure RTD Foundation, 6228 Northaven Road, Dallas, TX 75230, USA
| | - Marco Tartaglia
- Genetics and Rare Diseases Research Division, IRCCS Ospedale Pediatrico Bambino Gesù, Rome 00146, Italy
| | - Enrico Bertini
- Department of Neuroscience, Unit of Neuromuscular and Neurodegenerative Diseases, Laboratory of Molecular Medicine, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ospedale Pediatrico Bambino Gesù, Rome 00146, Italy
- Genetics and Rare Diseases Research Division, IRCCS Ospedale Pediatrico Bambino Gesù, Rome 00146, Italy
| | - Sandra Moreno
- Department of Science, Laboratorio Interdipartimentale di Microscopia Elettronica, University Roma Tre, Rome 00146, Italy
| | - Claudia Compagnucci
- Genetics and Rare Diseases Research Division, IRCCS Ospedale Pediatrico Bambino Gesù, Rome 00146, Italy
| |
Collapse
|
6
|
Mutlu B, Topçu MT, Çiprut A. A Case with Brown-Vialetto-Van Laere Syndrome: A Sudden Onset Auditory Neuropathy Spectrum Disorder. Turk Arch Otorhinolaryngol 2019; 57:201-205. [PMID: 32128519 DOI: 10.5152/tao.2019.4639] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2019] [Accepted: 11/10/2019] [Indexed: 11/22/2022] Open
Abstract
The Brown-Vialetto-Van Laere syndrome (BVVLS) is a rare neurological disorder that may present at all ages with sensorineural hearing loss, bulbar palsy and respiratory compromise. We describe a 6-year-old male patient who suffered bilateral sudden onset severe hearing loss for two years. Audiological investigations revealed sudden onset auditory neuropathy spectrum disorder bilaterally. He also had neurological complaints. During riboflavin therapy an improvement in hearing loss and the benefit of hearing aids were observed. In BVVLS, it is difficult to plan and apply auditory rehabilitation interventions and the results vary from patient to patient. In audiological evaluation, it should be borne in mind that subjective and objective tests are complemental. Early medical intervention and regular audiological follow-up are very important for effective hearing rehabilitation in the patients with BVVLS.
Collapse
Affiliation(s)
- Başak Mutlu
- Department of Audiology, İstanbul Medeniyet University School of Health Sciences, İstanbul, Turkey
| | - Merve Torun Topçu
- Department of Audiology, İstanbul Medeniyet University School of Health Sciences, İstanbul, Turkey
| | - Ayça Çiprut
- Department of Audiology, Marmara University School of Medicine, İstanbul, Turkey
| |
Collapse
|
7
|
Anderson P, Schaefer S, Henderson L, Bruce IA. Cochlear implantation in children with auditory neuropathy: Lessons from Brown–Vialetto–Van Laere syndrome. Cochlear Implants Int 2018; 20:31-38. [DOI: 10.1080/14670100.2018.1534035] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Phoebe Anderson
- Manchester Medical School, University of Manchester, Manchester, UK
| | - Simone Schaefer
- Paediatric ENT Department, Royal Manchester Children’s Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | - Lise Henderson
- Richard Ramsden Centre for Auditory Implants, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
| | - Iain A. Bruce
- Paediatric ENT Department, Royal Manchester Children’s Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK
- Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
| |
Collapse
|
8
|
Abbas Q, Jafri SK, Ishaque S, Rahman AJ. Brown-Vialetto-Van Laere syndrome: a novel diagnosis to a common presentation. BMJ Case Rep 2018; 2018:bcr-2018-224958. [PMID: 29950502 DOI: 10.1136/bcr-2018-224958] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
Brown-Vialetto-Van Laere syndrome (BVVLS) or riboflavin transporter deficiency (OMIM 211530) is a rare treatable autosomal recessive neurodegenerative disorder. This condition is associated with progressive pontobulbar palsy. We describe the clinical course of a 16-month-old boy with BVVLS and a novel homozygous mutation from Pakistan. Our patient presented with stridor and respiratory insufficiency. Hearing loss which is the most common sign of this condition was absent, making it an unusual presentation of BVVLS. His examination revealed ptosis and tongue fasciculation. His riboflavin receptor mutational analysis showed the homozygous mutation in the SLC52A3 gene. Per oral riboflavin was administered, and subsequently, he was able to be weaned off the ventilator. Now the child is improving and attaining developmental milestones.
Collapse
Affiliation(s)
- Qalab Abbas
- Department of Pediatrics and Child Health, Aga Khan University Hospital, Karachi, Pakistan
| | - Sidra Kaleem Jafri
- Department of Pediatrics and Child Health, Aga Khan University Hospital, Karachi, Pakistan
| | - Sidra Ishaque
- Department of Pediatrics and Child Health, Aga Khan University Hospital, Karachi, Pakistan
| | | |
Collapse
|
9
|
Garg M, Kulkarni SD, Hegde AU, Shah KN. Riboflavin Treatment in Genetically Proven Brown-Vialetto-Van Laere Syndrome. J Pediatr Neurosci 2018; 13:471-473. [PMID: 30937093 PMCID: PMC6413615 DOI: 10.4103/jpn.jpn_131_17] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Brown–Vialetto–Van Laere (BVVL) syndrome is a rare motor neuron disorder of childhood, which forms a continuous spectrum with Fazio–Londe syndrome. It is an autosomal-recessive inherited disease caused by mutations in intestinal riboflavin transporter genes. We describe a child with genetically proven BVVL syndrome where prompt treatment with riboflavin showed good results.
Collapse
Affiliation(s)
- Meenal Garg
- Department of Pediatric Neurosciences, Bai Jerbai Wadia Hospital for Children, Acharya Donde Marg, Parel, Mumbai, Maharashtra, India
| | - Shilpa D Kulkarni
- Department of Pediatric Neurosciences, Bai Jerbai Wadia Hospital for Children, Acharya Donde Marg, Parel, Mumbai, Maharashtra, India
| | - Anaita U Hegde
- Department of Pediatric Neurosciences, Bai Jerbai Wadia Hospital for Children, Acharya Donde Marg, Parel, Mumbai, Maharashtra, India
| | - Krishnakumar N Shah
- Department of Pediatric Neurosciences, Bai Jerbai Wadia Hospital for Children, Acharya Donde Marg, Parel, Mumbai, Maharashtra, India
| |
Collapse
|
10
|
Menezes MP, O'Brien K, Hill M, Webster R, Antony J, Ouvrier R, Birman C, Gardner-Berry K. Auditory neuropathy in Brown-Vialetto-Van Laere syndrome due to riboflavin transporter RFVT2 deficiency. Dev Med Child Neurol 2016; 58:848-54. [PMID: 26918385 DOI: 10.1111/dmcn.13084] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 12/24/2015] [Indexed: 12/17/2022]
Abstract
AIM Mutations in the genes encoding the riboflavin transporters RFVT2 and RFVT3 have been identified in Brown-Vialetto-Van Laere syndrome, a neurodegenerative disorder characterized by hearing loss and pontobulbar palsy. Treatment with riboflavin has been shown to benefit individuals with the phenotype of RFVT2 deficiency. Understanding the characteristics of hearing loss in riboflavin transporter deficiency would enable early diagnosis and therapy. METHOD We performed hearing assessments in seven children (from four families) with RFVT2 deficiency and reviewed results from previous assessments. Assessments were repeated after 12 months and 24 months of riboflavin therapy and after cochlear implantation in one individual. RESULTS Hearing loss in these individuals was due to auditory neuropathy spectrum disorder (ANSD). Hearing loss was identified between 3 years and 8 years of age and progressed rapidly. Hearing aids were not beneficial. Riboflavin therapy resulted in improvement of hearing thresholds during the first year of treatment in those with recent-onset hearing loss. Cochlear implantation resulted in a significant improvement in speech perception in one individual. INTERPRETATION Riboflavin transporter deficiency should be considered in all children presenting with an auditory neuropathy. Speech perception in children with ANSD due to RFVT2 deficiency may be significantly improved by cochlear implantation.
Collapse
Affiliation(s)
- Manoj P Menezes
- Institute for Neuroscience and Muscle Research and Discipline of Paediatrics and Child Health, The Children's Hospital at Westmead, Sydney, NSW, Australia
| | - Katherine O'Brien
- Department of Audiology, The Children's Hospital at Westmead, Sydney, NSW, Australia
| | - Mandy Hill
- Sydney Cochlear Implant Centre, Sydney, NSW, Australia
| | - Richard Webster
- Institute for Neuroscience and Muscle Research and Discipline of Paediatrics and Child Health, The Children's Hospital at Westmead, Sydney, NSW, Australia
| | - Jayne Antony
- Institute for Neuroscience and Muscle Research and Discipline of Paediatrics and Child Health, The Children's Hospital at Westmead, Sydney, NSW, Australia
| | - Robert Ouvrier
- Institute for Neuroscience and Muscle Research and Discipline of Paediatrics and Child Health, The Children's Hospital at Westmead, Sydney, NSW, Australia
| | - Catherine Birman
- Department of ENT and Discipline of Paediatrics and Child Health, The Children's Hospital at Westmead, Sydney, NSW, Australia
| | | |
Collapse
|
11
|
|
12
|
Foley AR, Menezes MP, Pandraud A, Gonzalez MA, Al-Odaib A, Abrams AJ, Sugano K, Yonezawa A, Manzur AY, Burns J, Hughes I, McCullagh BG, Jungbluth H, Lim MJ, Lin JP, Megarbane A, Urtizberea JA, Shah AH, Antony J, Webster R, Broomfield A, Ng J, Mathew AA, O’Byrne JJ, Forman E, Scoto M, Prasad M, O’Brien K, Olpin S, Oppenheim M, Hargreaves I, Land JM, Wang MX, Carpenter K, Horvath R, Straub V, Lek M, Gold W, Farrell MO, Brandner S, Phadke R, Matsubara K, McGarvey ML, Scherer SS, Baxter PS, King MD, Clayton P, Rahman S, Reilly MM, Ouvrier RA, Christodoulou J, Züchner S, Muntoni F, Houlden H. Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain 2014; 137:44-56. [PMID: 24253200 PMCID: PMC3891447 DOI: 10.1093/brain/awt315] [Citation(s) in RCA: 115] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Revised: 09/09/2013] [Accepted: 09/20/2013] [Indexed: 11/12/2022] Open
Abstract
Childhood onset motor neuron diseases or neuronopathies are a clinically heterogeneous group of disorders. A particularly severe subgroup first described in 1894, and subsequently called Brown-Vialetto-Van Laere syndrome, is characterized by progressive pontobulbar palsy, sensorineural hearing loss and respiratory insufficiency. There has been no treatment for this progressive neurodegenerative disorder, which leads to respiratory failure and usually death during childhood. We recently reported the identification of SLC52A2, encoding riboflavin transporter RFVT2, as a new causative gene for Brown-Vialetto-Van Laere syndrome. We used both exome and Sanger sequencing to identify SLC52A2 mutations in patients presenting with cranial neuropathies and sensorimotor neuropathy with or without respiratory insufficiency. We undertook clinical, neurophysiological and biochemical characterization of patients with mutations in SLC52A2, functionally analysed the most prevalent mutations and initiated a regimen of high-dose oral riboflavin. We identified 18 patients from 13 families with compound heterozygous or homozygous mutations in SLC52A2. Affected individuals share a core phenotype of rapidly progressive axonal sensorimotor neuropathy (manifesting with sensory ataxia, severe weakness of the upper limbs and axial muscles with distinctly preserved strength of the lower limbs), hearing loss, optic atrophy and respiratory insufficiency. We demonstrate that SLC52A2 mutations cause reduced riboflavin uptake and reduced riboflavin transporter protein expression, and we report the response to high-dose oral riboflavin therapy in patients with SLC52A2 mutations, including significant and sustained clinical and biochemical improvements in two patients and preliminary clinical response data in 13 patients with associated biochemical improvements in 10 patients. The clinical and biochemical responses of this SLC52A2-specific cohort suggest that riboflavin supplementation can ameliorate the progression of this neurodegenerative condition, particularly when initiated soon after the onset of symptoms.
Collapse
Affiliation(s)
- A. Reghan Foley
- 1 Dubowitz Neuromuscular Centre and MRC Centre for Neuromuscular Disorders, University College London Institute of Child Health and Great Ormond Street Hospital for Children, London, WC1N 1EH, UK
| | - Manoj P. Menezes
- 2 Institute for Neuroscience and Muscle Research, The Children’s Hospital at Westmead, Sydney, New South Wales, 2145, Australia
- 3 Discipline of Paediatrics and Child Health, The University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Amelie Pandraud
- 4 Department of Molecular Neuroscience and the MRC Centre for Neuromuscular Diseases, University College London Institute of Neurology and the Neurometabolic Unit, The National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK
| | - Michael A. Gonzalez
- 5 Dr. John T. Macdonald Foundation Department of Human Genetics and Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, 33136, USA
| | - Ahmad Al-Odaib
- 3 Discipline of Paediatrics and Child Health, The University of Sydney, Sydney, New South Wales, 2006, Australia
- 6 Western Sydney Genetics Program, The Children’s Hospital at Westmead, Sydney, New South Wales, 2145, Australia
- 7 Department of Genetics, King Faisal Specialist Hospital and Research Centre, Riyadh, 12713, Saudi Arabia
| | - Alexander J. Abrams
- 5 Dr. John T. Macdonald Foundation Department of Human Genetics and Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, 33136, USA
| | - Kumiko Sugano
- 8 Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan
| | - Atsushi Yonezawa
- 8 Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan
| | - Adnan Y. Manzur
- 1 Dubowitz Neuromuscular Centre and MRC Centre for Neuromuscular Disorders, University College London Institute of Child Health and Great Ormond Street Hospital for Children, London, WC1N 1EH, UK
| | - Joshua Burns
- 2 Institute for Neuroscience and Muscle Research, The Children’s Hospital at Westmead, Sydney, New South Wales, 2145, Australia
- 3 Discipline of Paediatrics and Child Health, The University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Imelda Hughes
- 9 Department of Paediatric Neurology, Royal Manchester Children’s Hospital, Manchester, M13 9WL, UK
| | - B. Gary McCullagh
- 9 Department of Paediatric Neurology, Royal Manchester Children’s Hospital, Manchester, M13 9WL, UK
| | - Heinz Jungbluth
- 10 Department of Paediatric Neurology, Evelina Children’s Hospital, St. Thomas’ Hospital, London, SE1 7EH, UK
- 11 Randall Division of Cell and Molecular Biophysics, Muscle Signalling Section, King’s College, London, WC2R 2LS, UK
- 12 Clinical Neuroscience Division, Institute of Psychiatry, King’s College, London, WC2R 2LS, UK
| | - Ming J. Lim
- 10 Department of Paediatric Neurology, Evelina Children’s Hospital, St. Thomas’ Hospital, London, SE1 7EH, UK
| | - Jean-Pierre Lin
- 10 Department of Paediatric Neurology, Evelina Children’s Hospital, St. Thomas’ Hospital, London, SE1 7EH, UK
| | - Andre Megarbane
- 13 Unité de Génétique Médicale et laboratoire associe INSERM UMR S_910, Faculté de Médecine, Université Saint Joseph, Beirut, 1104 2020, Lebanon
| | | | - Ayaz H. Shah
- 15 Royal Aberdeen Children’s Hospital, Aberdeen, AB15 6XS, UK
| | - Jayne Antony
- 2 Institute for Neuroscience and Muscle Research, The Children’s Hospital at Westmead, Sydney, New South Wales, 2145, Australia
| | - Richard Webster
- 2 Institute for Neuroscience and Muscle Research, The Children’s Hospital at Westmead, Sydney, New South Wales, 2145, Australia
| | - Alexander Broomfield
- 16 Metabolic Medicine Unit, Great Ormond Street Hospital for Children, London, WC1N 3JH, UK
| | - Joanne Ng
- 17 Neurology Department, Great Ormond Street Hospital for Children, London, WC1N 3JH, UK
| | - Ann A. Mathew
- 17 Neurology Department, Great Ormond Street Hospital for Children, London, WC1N 3JH, UK
| | - James J. O’Byrne
- 18 Department of Paediatric Neurology, Children’s University Hospital, Dublin, 1, Ireland
| | - Eva Forman
- 18 Department of Paediatric Neurology, Children’s University Hospital, Dublin, 1, Ireland
| | - Mariacristina Scoto
- 1 Dubowitz Neuromuscular Centre and MRC Centre for Neuromuscular Disorders, University College London Institute of Child Health and Great Ormond Street Hospital for Children, London, WC1N 1EH, UK
| | - Manish Prasad
- 19 Department of Paediatric Neurology, Sheffield Children’s Hospital, Sheffield, S10 2TH, UK
| | - Katherine O’Brien
- 20 Department of Audiology, The Children’s Hospital at Westmead, Sydney, New South Wales, 2145, Australia
| | - Simon Olpin
- 21 Clinical Chemistry, Sheffield Children’s Hospital, Sheffield, S10 2TH, UK
| | - Marcus Oppenheim
- 4 Department of Molecular Neuroscience and the MRC Centre for Neuromuscular Diseases, University College London Institute of Neurology and the Neurometabolic Unit, The National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK
| | - Iain Hargreaves
- 4 Department of Molecular Neuroscience and the MRC Centre for Neuromuscular Diseases, University College London Institute of Neurology and the Neurometabolic Unit, The National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK
| | - John M. Land
- 4 Department of Molecular Neuroscience and the MRC Centre for Neuromuscular Diseases, University College London Institute of Neurology and the Neurometabolic Unit, The National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK
| | - Min X. Wang
- 22 Institute of Clinical Neurosciences, Royal Prince Alfred Hospital, Sydney, New South Wales, 2050, Australia
| | - Kevin Carpenter
- 3 Discipline of Paediatrics and Child Health, The University of Sydney, Sydney, New South Wales, 2006, Australia
- 23 Discipline of Genetic Medicine, The University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Rita Horvath
- 24 Institute of Genetic Medicine, International Centre for Life, University of Newcastle, Newcastle upon Tyne, NE1 3BZ, UK
| | - Volker Straub
- 24 Institute of Genetic Medicine, International Centre for Life, University of Newcastle, Newcastle upon Tyne, NE1 3BZ, UK
| | - Monkol Lek
- 2 Institute for Neuroscience and Muscle Research, The Children’s Hospital at Westmead, Sydney, New South Wales, 2145, Australia
| | - Wendy Gold
- 3 Discipline of Paediatrics and Child Health, The University of Sydney, Sydney, New South Wales, 2006, Australia
- 6 Western Sydney Genetics Program, The Children’s Hospital at Westmead, Sydney, New South Wales, 2145, Australia
| | | | - Sebastian Brandner
- 26 Division of Neuropathology, UCL Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK
| | - Rahul Phadke
- 1 Dubowitz Neuromuscular Centre and MRC Centre for Neuromuscular Disorders, University College London Institute of Child Health and Great Ormond Street Hospital for Children, London, WC1N 1EH, UK
- 26 Division of Neuropathology, UCL Institute of Neurology, The National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK
| | - Kazuo Matsubara
- 8 Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital, Sakyo-ku, Kyoto, 606-8507, Japan
| | - Michael L. McGarvey
- 27 Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA
| | - Steven S. Scherer
- 27 Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, 19104, USA
| | - Peter S. Baxter
- 19 Department of Paediatric Neurology, Sheffield Children’s Hospital, Sheffield, S10 2TH, UK
| | - Mary D. King
- 18 Department of Paediatric Neurology, Children’s University Hospital, Dublin, 1, Ireland
| | - Peter Clayton
- 28 Clinical and Molecular Genetics Unit, University College London Institute of Child Health and Great Ormond Street Hospital for Children, London, WC1N 1EH, UK
| | - Shamima Rahman
- 4 Department of Molecular Neuroscience and the MRC Centre for Neuromuscular Diseases, University College London Institute of Neurology and the Neurometabolic Unit, The National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK
- 16 Metabolic Medicine Unit, Great Ormond Street Hospital for Children, London, WC1N 3JH, UK
- 28 Clinical and Molecular Genetics Unit, University College London Institute of Child Health and Great Ormond Street Hospital for Children, London, WC1N 1EH, UK
| | - Mary M. Reilly
- 4 Department of Molecular Neuroscience and the MRC Centre for Neuromuscular Diseases, University College London Institute of Neurology and the Neurometabolic Unit, The National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK
| | - Robert A. Ouvrier
- 2 Institute for Neuroscience and Muscle Research, The Children’s Hospital at Westmead, Sydney, New South Wales, 2145, Australia
- 3 Discipline of Paediatrics and Child Health, The University of Sydney, Sydney, New South Wales, 2006, Australia
| | - John Christodoulou
- 3 Discipline of Paediatrics and Child Health, The University of Sydney, Sydney, New South Wales, 2006, Australia
- 6 Western Sydney Genetics Program, The Children’s Hospital at Westmead, Sydney, New South Wales, 2145, Australia
- 23 Discipline of Genetic Medicine, The University of Sydney, Sydney, New South Wales, 2006, Australia
| | - Stephan Züchner
- 5 Dr. John T. Macdonald Foundation Department of Human Genetics and Hussman Institute for Human Genomics, University of Miami Miller School of Medicine, Miami, Florida, 33136, USA
| | - Francesco Muntoni
- 1 Dubowitz Neuromuscular Centre and MRC Centre for Neuromuscular Disorders, University College London Institute of Child Health and Great Ormond Street Hospital for Children, London, WC1N 1EH, UK
| | - Henry Houlden
- 4 Department of Molecular Neuroscience and the MRC Centre for Neuromuscular Diseases, University College London Institute of Neurology and the Neurometabolic Unit, The National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3BG, UK
| |
Collapse
|
13
|
Bandettini Di Poggio M, Monti Bragadin M, Reni L, Doria-Lamba L, Cereda C, Pardini M, Roccatagliata L, Rossi A, Schenone A. Brown-Vialetto-Van Laere syndrome: clinical and neuroradiological findings of a genetically proven patient. Amyotroph Lateral Scler Frontotemporal Degener 2013; 15:141-4. [PMID: 24079556 DOI: 10.3109/21678421.2013.837931] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
The Brown-Vialetto-Van Laere syndrome (BVVLS) is a rare neurological disorder characterized by progressive pontobulbar palsy, sensorineural deafness and mixed spinal and upper motor neuropathy. Mutations in the C20orf54 gene have been linked to the disease and recently we reported the first Italian case of a BVVLS family with an intriguing C20orf54 genotype. However, the pathomechanisms underlying BVVLS are still unknown. Here we present the particular disease course with partial response to immunosuppressive therapy of our BVVLS patient for whom we hypothesize that dysimmune factors may have played a role in disease physiopathology.
Collapse
Affiliation(s)
- Monica Bandettini Di Poggio
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Bandettini di Poggio M, Gagliardi S, Pardini M, Marchioni E, Monti Bragadin M, Reni L, Doria-Lamba L, Roccatagliata L, Ceroni M, Schenone A, Cereda C. A novel compound heterozygous mutation ofC20orf54gene associated with Brown-Vialetto-Van Laere syndrome in an Italian family. Eur J Neurol 2013; 20:e94-5. [DOI: 10.1111/ene.12163] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2012] [Accepted: 02/28/2013] [Indexed: 12/01/2022]
Affiliation(s)
- M. Bandettini di Poggio
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health; University of Genoa; Genoa Italy
| | - S. Gagliardi
- Laboratory of Experimental Neurobiology; ‘C. Mondino’ National Institute of Neurology Foundation; IRCCS; Pavia Italy
| | - M. Pardini
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health; University of Genoa; Genoa Italy
| | - E. Marchioni
- Department of General Neurology; ‘C. Mondino’ National Institute of Neurology Foundation; IRCCS; Pavia Italy
| | - M. Monti Bragadin
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health; University of Genoa; Genoa Italy
- Don Carlo Gnocchi Onlus Foundation; Milan Italy
| | - L. Reni
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health; University of Genoa; Genoa Italy
| | - L. Doria-Lamba
- Children Neuropsychiatry Operative Unit; G. Gaslini Institute; Genoa Italy
| | - L. Roccatagliata
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health; University of Genoa; Genoa Italy
| | - M. Ceroni
- Department of General Neurology; ‘C. Mondino’ National Institute of Neurology Foundation; IRCCS; Pavia Italy
- Don Carlo Gnocchi Onlus Foundation; Milan Italy
- Children Neuropsychiatry Operative Unit; G. Gaslini Institute; Genoa Italy
- Department of Public Health, Neuroscience, Experimental and Forensic Medicine; University of Pavia; Pavia Italy
| | - A. Schenone
- Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health; University of Genoa; Genoa Italy
| | - C. Cereda
- Laboratory of Experimental Neurobiology; ‘C. Mondino’ National Institute of Neurology Foundation; IRCCS; Pavia Italy
| |
Collapse
|
15
|
Brown–Vialetto–van Laere and Fazio–Londe overlap syndromes: A clinical, biochemical and genetic study. Neuromuscul Disord 2012; 22:1075-82. [DOI: 10.1016/j.nmd.2012.05.007] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2011] [Revised: 05/01/2012] [Accepted: 05/18/2012] [Indexed: 12/14/2022]
|
16
|
Bosch AM, Stroek K, Abeling NG, Waterham HR, Ijlst L, Wanders RJA. The Brown-Vialetto-Van Laere and Fazio Londe syndrome revisited: natural history, genetics, treatment and future perspectives. Orphanet J Rare Dis 2012; 7:83. [PMID: 23107375 PMCID: PMC3517535 DOI: 10.1186/1750-1172-7-83] [Citation(s) in RCA: 90] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2012] [Accepted: 10/23/2012] [Indexed: 11/24/2022] Open
Abstract
The Brown-Vialetto-Van Laere syndrome is a rare neurological disorder which may present at all ages with sensorineural deafness, bulbar palsy and respiratory compromise. Fazio-Londe syndrome is considered to be the same disease entity. Recently it was demonstrated that in some patients the disease is caused by mutations in the SLC52A3 gene which encodes the intestinal (hRFT2) riboflavin transporter. In these patients riboflavin deficiency is the cause of the BVVL/FL syndrome and supplementation of riboflavin proved a life saving treatment. Mutations in the SLC52A2 gene and the SLC52A1 (GPR172B) gene, coding for human riboflavin transporters hRFT3 and hRFT1 have been associated with the BVVL syndrome as well. We performed a review of the literature, with emphasis on the natural history and the effects of treatment in these patients. A total of 35 publications were traced reporting on the clinical presentation of 74 patients who presented before age 18. The most prevalent symptoms were bulbar palsy, hearing loss, facial weakness and respiratory compromise. Death was reported in 28 of the 61 untreated patients, with a very low survival in patients presenting before age 4. All 13 patients who were treated with riboflavin survived, with a strong clinical improvement after days to months of treatment in eight patients. Three patients demonstrated a stable clinical course and treatment was stopped early in two patients. Abnormalities in plasma flavin levels and/or plasma acylcarnitine profiles were observed in some but not in all patients, and also patients with normal plasma flavin levels and acylcarnitine profiles demonstrated a striking clinical improvement on riboflavin supplementation. It is now clear that proper diagnosis requires mutation analysis of all three transporter genes and treatment should be started immediately without first awaiting results of molecular analysis. Clinical improvement may be rapid or gradual over a period of more than 12 months.
Collapse
Affiliation(s)
- Annet M Bosch
- Department of Pediatrics, University of Amsterdam, Amsterdam, The Netherlands.
| | | | | | | | | | | |
Collapse
|
17
|
Johnson JO, Gibbs JR, Megarbane A, Urtizberea JA, Hernandez DG, Foley AR, Arepalli S, Pandraud A, Simón-Sánchez J, Clayton P, Reilly MM, Muntoni F, Abramzon Y, Houlden H, Singleton AB. Exome sequencing reveals riboflavin transporter mutations as a cause of motor neuron disease. ACTA ACUST UNITED AC 2012; 135:2875-82. [PMID: 22740598 DOI: 10.1093/brain/aws161] [Citation(s) in RCA: 99] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Brown-Vialetto-Van Laere syndrome was first described in 1894 as a rare neurodegenerative disorder characterized by progressive sensorineural deafness in combination with childhood amyotrophic lateral sclerosis. Mutations in the gene, SLC52A3 (formerly C20orf54), one of three known riboflavin transporter genes, have recently been shown to underlie a number of severe cases of Brown-Vialetto-Van Laere syndrome; however, cases and families with this disease exist that do not appear to be caused by SLC52A3 mutations. We used a combination of linkage and exome sequencing to identify the disease causing mutation in an extended Lebanese Brown-Vialetto-Van Laere kindred, whose affected members were negative for SLC52A3 mutations. We identified a novel mutation in a second member of the riboflavin transporter gene family (gene symbol: SLC52A2) as the cause of disease in this family. The same mutation was identified in one additional subject, from 44 screened. Within this group of 44 patients, we also identified two additional cases with SLC52A3 mutations, but none with mutations in the remaining member of this gene family, SLC52A1. We believe this strongly supports the notion that defective riboflavin transport plays an important role in Brown-Vialetto-Van Laere syndrome. Initial work has indicated that patients with SLC52A3 defects respond to riboflavin treatment clinically and biochemically. Clearly, this makes an excellent candidate therapy for the SLC52A2 mutation-positive patients identified here. Initial riboflavin treatment of one of these patients shows promising results.
Collapse
Affiliation(s)
- Janel O Johnson
- Laboratory of Neurogenetics, National Institute on Ageing, National Institutes of Health, Bethesda, MD 20892, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Four novel C20orf54 mutations identified in Brown–Vialetto–Van Laere syndrome patients. J Hum Genet 2012; 57:613-7. [DOI: 10.1038/jhg.2012.70] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
19
|
Moustafa H, Omar T, Sami Y. Brown–Vialetto–Van Laere syndrome: Egyptian case report. ALEXANDRIA JOURNAL OF MEDICINE 2012. [DOI: 10.1016/j.ajme.2011.08.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- Hayam Moustafa
- Department of Physical Medicine, Rheumatology and Rehabilitation , Alexandria Faculty of Medicine , Alexandria University , Egypt
| | - Tarek Omar
- Department of Pediatrics, Alexandria Faculty of Medicine , Alexandria University , Egypt
| | - Yaser Sami
- Department of Pediatrics, Alexandria Faculty of Medicine , Alexandria University , Egypt
| |
Collapse
|
20
|
Davenport R, Mumford C. The Brown-Vialetto-van Laere syndrome: a case report and literature review. Eur J Neurol 2011; 1:51-4. [DOI: 10.1111/j.1468-1331.1994.tb00050.x] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
21
|
Cochlear Implantation in Brown-Vialetto-Van-Laere syndrome. The Journal of Laryngology & Otology 2010; 125:314-7. [PMID: 20955635 DOI: 10.1017/s0022215110001982] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
OBJECTIVE To report outcomes for the first known cochlear implantation procedures in two patients with Brown-Vialetto-Van-Laere syndrome. PATIENTS Two adult patients (a brother and sister) with post-lingual sensorineural deafness associated with Brown-Vialetto-Van-Laere syndrome. The female patient presented with a milder form of the syndrome. INTERVENTION Cochlear implantation. MAIN OUTCOME MEASURE Post-implantation speech discrimination scores. RESULTS Auditory evoked potential testing suggested pathological changes in both patients' cochleae, auditory nerves, brainstem and (probably) central auditory pathways. In the male patient, despite implantation of the better ear, the Bamford-Kowal-Bench sentence score was zero at 21 months post-implantation. In the female patient, Bamford-Kowal-Bench sentence scores at six months post-implantation were 25 per cent in quiet and 3 per cent in noise. CONCLUSION These poor clinical outcomes appear to be related to retrocochlear and probable central auditory pathway degeneration.
Collapse
|
22
|
Green P, Wiseman M, Crow YJ, Houlden H, Riphagen S, Lin JP, Raymond FL, Childs AM, Sheridan E, Edwards S, Josifova DJ. Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in c20orf54. Am J Hum Genet 2010; 86:485-9. [PMID: 20206331 DOI: 10.1016/j.ajhg.2010.02.006] [Citation(s) in RCA: 134] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2009] [Revised: 01/18/2010] [Accepted: 02/05/2010] [Indexed: 12/30/2022] Open
Abstract
Brown-Vialetto-Van Laere syndrome is a rare neurological disorder with a variable age at onset and clinical course. The key features are progressive ponto-bulbar palsy and bilateral sensorineural deafness. A complex neurological phenotype with a mixed picture of upper and lower motor neuron involvement reminiscent of amyotrophic lateral sclerosis evolves with disease progression. We identified a candidate gene, C20orf54, by studying a consanguineous family with multiple affected individuals and subsequently demonstrated that mutations in this gene were the cause of disease in other, unrelated families.
Collapse
Affiliation(s)
- Peter Green
- Department of Medical and Molecular Genetics, Kings College, London, SE1 9RT, UK
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Koç AF, Bozdemir H, Sarıca Y. Mental retardation associated with Brown‐Vialetto‐Van Laere syndromeSirs. ACTA ACUST UNITED AC 2009. [DOI: 10.1080/14660820310006742] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
24
|
Sathasivam S. Brown-Vialetto-Van Laere syndrome. Orphanet J Rare Dis 2008; 3:9. [PMID: 18416855 PMCID: PMC2346457 DOI: 10.1186/1750-1172-3-9] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2007] [Accepted: 04/17/2008] [Indexed: 11/21/2022] Open
Abstract
The Brown-Vialetto-Van Laere syndrome (BVVL) is a rare neurological disorder characterized by progressive pontobulbar palsy associated with sensorineural deafness. Fifty-eight cases have been reported in just over 100 years. The female to male ratio is approximately 3:1. The age of onset of the initial symptom varies from infancy to the third decade. The syndrome most frequently presents with sensorineural deafness, which is usually progressive and severe. Lower cranial nerve involvement and lower and upper motor neuron limb signs are common neurological features. Other features include respiratory compromise (the most frequent non-neurological finding), limb weakness, slurring of speech, facial weakness, and neck and shoulder weakness. Optic atrophy, retinitis pigmentosa, macular hyperpigmentation, autonomic dysfunction, epilepsy may occur. The etiopathogenesis of the condition remains elusive. Approximately 50% of cases are familial, of which autosomal recessive is suggested. The remaining cases are sporadic. The diagnosis is usually based on the clinical presentation. Investigations (neurophysiological studies, magnetic resonance imaging of the brain, muscle biopsy, cerebrospinal fluid examination) are done to exclude other causes or to confirm the clinical findings. The differential diagnoses include the Fazio-Londe syndrome, amyotrophic lateral sclerosis, Nathalie syndrome, Boltshauser syndrome and Madras motor neuron disease. Treatment with steroids or intravenous immunoglobulin may result in temporary stabilization of the syndrome. However, the mainstays of management are supportive and symptomatic treatment, in particular assisted ventilation and maintenance of nutrition via gastrostomy. The clinical course of BVVL is variable and includes gradual deterioration (almost half of cases), gradual deterioration with stable periods in between (a third of cases) and deterioration with abrupt periods of worsening (just under a fifth of cases). After the initial presentation, one third of patients survive for ten years or longer.
Collapse
|
25
|
Malheiros JA, Camargos ST, Oliveira JTD, Cardoso FEC. A Brazilian family with Brown-Vialetto-van Laere syndrome with autosomal recessive inheritance. ARQUIVOS DE NEURO-PSIQUIATRIA 2007; 65:32-5. [PMID: 17420823 DOI: 10.1590/s0004-282x2007000100008] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/29/2006] [Accepted: 10/23/2006] [Indexed: 11/22/2022]
Abstract
We report the first Brazilian family with Brown-Vialetto-van Laere syndrome. The presence of consanguineous marriages and illness affecting three sisters and one niece support an autosomal recessive transmission. The age at onset of the illness ranged from 12 to 20 years old. The time interval between hearing loss and involvement of other cranial nerves varied from 3 to 12 years. MRI demonstrated bulbar atrophy and also high intensity signal at T2 weighted and fluid attenuated inversion recovery (FLAIR) sequences.
Collapse
Affiliation(s)
- José Augusto Malheiros
- Neurology Service, Department of Internal Medicine, Medical School, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil
| | | | | | | |
Collapse
|
26
|
De Grandis D, Passadore P, Chinaglia M, Brazzo F, Ravenni R, Cudia P. Clinical features and neurophysiological follow-up in a case of Brown-Vialetto-Van Laere syndrome. Neuromuscul Disord 2005; 15:565-8. [PMID: 16009552 DOI: 10.1016/j.nmd.2005.05.003] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2004] [Revised: 04/07/2005] [Accepted: 05/04/2005] [Indexed: 11/18/2022]
Abstract
Brown-Vialetto-Van Laere syndrome is a rare disease of unknown origin commonly considered as part of the large group of motor neuron diseases. The course is quite variable: it may be quickly fatal or protracted, with relapsing phases followed by periods of arrest and even partial improvement. We describe a case of Brown-Vialetto-Van Laere syndrome with strong family history for sensorineural hearing impairment. The patient came to our medical attention for severe respiratory failure and leg weakness. The clinical conditions partially improved with recovery of spontaneous respiration and mild increase in muscle strength. The neurophysiological studies performed on our patient showed evidence of nerve damage with subsequent improvement. Our study raises the possibility that the disorder is due to primary nerve damage, which can better justify the intermittent course of the disease, the partial clinical regression and the neurophysiological improvement, never detected in typical motor neuron disorders.
Collapse
Affiliation(s)
- D De Grandis
- Department of Neurology, Rovigo Hospital, Ospedale Civile Rovigo, Viale Tre Martiri, 45100 Rovigo, Italy.
| | | | | | | | | | | |
Collapse
|
27
|
Dipti S, Childs AM, Livingston JH, Aggarwal AK, Miller M, Williams C, Crow YJ. Brown-Vialetto-Van Laere syndrome; variability in age at onset and disease progression highlighting the phenotypic overlap with Fazio-Londe disease. Brain Dev 2005; 27:443-6. [PMID: 16122634 DOI: 10.1016/j.braindev.2004.10.003] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/03/2004] [Revised: 10/01/2004] [Accepted: 10/14/2004] [Indexed: 10/26/2022]
Abstract
We report four siblings showing features of a pontobulbar palsy, a mixed spinal and upper motor neuropathy and variable deafness. The observation of affected males and females born to consanguineous first cousin parents suggests autosomal recessive inheritance. Two children presented in the first 16 months of life with stridor and died of respiratory failure by the age of 2 years. Hearing loss was not apparent in these infants. In contrast, 2 further siblings developed a bulbar palsy in their sixth year followed by the onset of deafness and features of an anterior horn neuropathy with corticospinal tract involvement. They exhibited a relatively slow but relentless decline over a period of several years. These cases highlight the phenotypic overlap of Brown-Vialetto-Van Laere syndrome with Fazio-Londe disease. Rather than representing two separate disorders, our findings suggest the possibility of a single disease entity which may usefully be considered a form of juvenile amyotrophic lateral sclerosis.
Collapse
|
28
|
Abstract
A 12-month-old boy with progressive cranial nerve palsies followed by ventilatory failure demanding artificial ventilation, generalized muscle weakness, and rapid progression to death at the age of 21 months is described. The patient had normal early development and also apparently normal hearing at presentation of illness but, after 6 months of the onset of the disease, hearing loss was documented by brainstem auditory evoked potentials (BAEP). Although the initial clinical and laboratory findings of this infant could fit with the diagnosis of progressive childhood bulbar palsy or Fazio-Londe (FL) disease, the subsequent appearance of hearing loss suggests that this patient represents a case of progressive bulbar palsy with perceptive deafness or Brown-Vialetto-Van Laere (BVVL) syndrome. To our knowledge, this case of BVVL syndrome with severe clinical features and rapid deterioration leading to death is the youngest one reported in the literature. Furthermore, this case emphasizes the need for repeated auditory examinations, including the performance of BAEP in all cases, especially infants and young children with progressive bulbar palsy.
Collapse
Affiliation(s)
- Konstantinos A Voudris
- Second Department of Paediatrics-University of Athens, P & A Kyriakou Children's Hospital, Thivon & Levadeias Street, 115 27, Athens, Greece.
| | | | | |
Collapse
|
29
|
Mégarbané A, Desguerres I, Rizkallah E, Delague V, Nabbout R, Barois A, Urtizberea A. Brown-Vialetto-Van Laere syndrome in a large inbred Lebanese family: confirmation of autosomal recessive inheritance? AMERICAN JOURNAL OF MEDICAL GENETICS 2000; 92:117-21. [PMID: 10797435 DOI: 10.1002/(sici)1096-8628(20000515)92:2<117::aid-ajmg7>3.0.co;2-c] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Brown-Vialetto-Van Laere syndrome or pontobulbar palsy with deafness is a rare disorder characterized by bilateral nerve deafness, a variety of cranial nerve disorders usually involving the motor components of the 7th and 9th to 12th cranial nerves, and less commonly an involvement of spinal motor nerves and upper motor neurons. Familial and sporadic cases have been reported. Based on particular evidence, autosomal recessive, autosomal dominant, and X-linked inheritance, as well as autoimmune origin have been considered. We report on a large inbred Lebanese family with four patients of both sexes, strongly suggesting autosomal recessive inheritance.
Collapse
Affiliation(s)
- A Mégarbané
- Unité de Génétique Médicale, Faculté de Médecine, Université Saint-Joseph, Beirut, Lebanon.
| | | | | | | | | | | | | |
Collapse
|
30
|
Abstract
Neurological, auditory, vestibular and ocular motor examinations were performed on 3 definite and 3 possible heterozygous carriers of a previously described X-linked multi-system disorder with early childhood onset, rapid progression and a fatal outcome (Arts et al., 1993). The symptoms, i.e., delayed motor development, ataxia, hearing loss and subnormal intelligence, were so evident in 2 of the possible carriers that they could be redesignated as probable carriers. Other symptoms in the definite and probable carriers were clubfeet, dysarthria, intention tremor and abnormal gait, while their signs included dysdiadochokinesia, ataxic paraplegia, abnormal muscle tendon reflexes and extensor plantar responses. All the symptomatic carriers developed moderate-to-severe sensorineural hearing loss with normal stapedial reflexes and brain stem auditory evoked potentials (BAEPs) in those in whom this could be evaluated. Speech discrimination was disproportionally poor unilaterally in one case from whom no BAEPs could be obtained because of her degree of hearing loss. Various combinations were found of high gain of the vestibulo-ocular reflex, spontaneous nystagmus and directional preponderance of vestibularly evoked nystagmus, slowing, hypometria or multi-stepping of saccades, saccadic intrusions of eye movements (macro square wave jerks, double saccadic pulses), impairment of smooth pursuit eye movements and optokinetic nystagmus, and failure of visual fixation suppression of vestibularly evoked nystagmus. Such findings indicate major involvement of the (vestibulo)cerebellum and the vermis. MRI in one carrier showed mild cerebellar atrophy.
Collapse
Affiliation(s)
- W I Verhagen
- Department of Neurology, Canisius-Wilhelmina Hospital, Nijmegen, The Netherlands
| | | | | |
Collapse
|
31
|
De Oliveira JT, Moreira PR, Cardoso F, Perpétuo FO. [Brown-Vialleto-van Laere syndrome: report of 2 cases]. ARQUIVOS DE NEURO-PSIQUIATRIA 1995; 53:789-91. [PMID: 8729774 DOI: 10.1590/s0004-282x1995000500013] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Brown-Vialetto-van Laere syndrome is a rare hereditary or sporadic degenerative disorder characterised by progressive sensoryneural deafness, followed or accompanied by cranial nerve palsies. The anterior horn cells and the optic pathways may be involved in some cases. We report two cases, and comment the differential diagnosis and the relationships of this syndrome to the muscle spinal atrophies and the hereditary deafness.
Collapse
Affiliation(s)
- J T De Oliveira
- Serviço de Neurologia, Universidade Federal de Minas Gerais, Brasil
| | | | | | | |
Collapse
|
32
|
Hamano K, Tsukamoto H, Yazawa T, Yoshimura M, Takita H. Infantile progressive spinal muscular atrophy with ophthalmoplegia and pyramidal symptoms. Pediatr Neurol 1994; 10:320-4. [PMID: 8068160 DOI: 10.1016/0887-8994(94)90130-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Two siblings presented with identical features of progressive peripheral paralysis of the lower motor neuron type, pyramidal signs, cranial nerve palsy which included external ocular palsy and deafness, and internal ocular palsy; both died before 1 year of age. Pathologic examination of the central nervous system in both patients revealed degeneration and loss of spinal and cranial nerve motor nuclei, including the oculomotor nucleus. In addition, there was degeneration of the Edinger-Westphal nuclei and demyelination of the corticospinal tract under the midbrain. Although spinal cord lesions were indistinguishable from those of Werdnig-Hoffmann disease, the 2 patients are not considered to have Werdnig-Hoffmann disease from the clinicopathologic findings.
Collapse
Affiliation(s)
- K Hamano
- Department of Pediatrics, University of Tsukuba, Japan
| | | | | | | | | |
Collapse
|
33
|
Abstract
The clinical and pathological findings of a male with the Brown-Vialetto-Van Laere syndrome are described. This rare and fatal affection of the nervous system involves mainly the brain stem with the prominent and early manifestation of sensorineural deafness. Increased awareness and documentation of this disorder has added information on the mode of inheritance.
Collapse
Affiliation(s)
- D A Francis
- National Hospital for Nervous Diseases, London
| | | | | | | | | |
Collapse
|
34
|
Piccolo G, Marchioni E, Maurelli M, Simonetti F, Bizzetti F, Savoldi F. Recovery from respiratory muscle failure in a sporadic case of Brown-Vialetto-Van Laere syndrome with unusually late onset. J Neurol 1992; 239:355-6. [PMID: 1512615 DOI: 10.1007/bf00867597] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
|
35
|
Abarbanel JM, Ashby P, Marquez-Julio A, Chapman KR. Bulbo-pontine paralysis with deafness: the Vialetto-Van Laere syndrome. Can J Neurol Sci 1991; 18:349-51. [PMID: 1913372 DOI: 10.1017/s0317167100031930] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
A Caucasian girl developed slowly progressive sensory neural deafness and bulbar and spinal muscle weakness typical of the Vialetto-Van Laere syndrome. As the condition progressed the major disabilities became dysphagia, respiratory muscle weakness and postural hypotension. Treatment with gastrostomy feedings, oxygen and fludrocortisone acetate produced worthwhile functional improvement.
Collapse
Affiliation(s)
- J M Abarbanel
- Electromyography Department, Toronto Hospital, Ontario, Canada
| | | | | | | |
Collapse
|
36
|
Hawkins SA, Nevin NC, Harding AE. Pontobulbar palsy and neurosensory deafness (Brown-Vialetto-Van Laere syndrome) with possible autosomal dominant inheritance. J Med Genet 1990; 27:176-9. [PMID: 2325091 PMCID: PMC1017000 DOI: 10.1136/jmg.27.3.176] [Citation(s) in RCA: 41] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
A female with the Brown-Vialetto-Van Laere syndrome is described. The patient's father, a paternal uncle, and possibly a paternal first cousin had neurosensory deafness and a paternal aunt had clinical symptoms indicative of the syndrome. This family raises the possibility that the disorder is genetically heterogeneous with autosomal recessive and autosomal dominant forms. Alternatively, it could be caused by a mutant gene on the X chromosome.
Collapse
Affiliation(s)
- S A Hawkins
- Department of Medicine, Queen's University of Belfast
| | | | | |
Collapse
|
37
|
Summers BA, Swash M, Schwartz MS, Ingram DA. Juvenile-onset bulbospinal muscular atrophy with deafness: Vialetta-van Laere syndrome or Madras-type motor neuron disease? J Neurol 1987; 234:440-2. [PMID: 3655850 DOI: 10.1007/bf00314095] [Citation(s) in RCA: 25] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
A girl with rapid-onset, bulbospinal muscular atrophy and deafness is described. The patient's mother and brother showed EMG features consistent with subclinical involvement. T is bulbospinal form of spinal muscular atrophy associated with deafness described by Vialetto and van Laere closely resembles the Madras type of motor neuron disease, also associated with deafness, described by Jagganathan and colleagues.
Collapse
Affiliation(s)
- B A Summers
- Department of Neurology, London Hospital, England
| | | | | | | |
Collapse
|